Defactinib

Drug Profile

Defactinib

Alternative Names: Defactinib hydrochloride; PF-04554878; PF-4554878; VS-6063

Latest Information Update: 14 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Pfizer
  • Developer Cancer Research UK; Pfizer; Verastem; Washington University
  • Class Antineoplastics; Benzamides; Pyrazines; Pyrimidines; Small molecules; Sulfones
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Mesothelioma; Non-small cell lung cancer
  • Phase I/II Ovarian cancer; Solid tumours
  • Phase I Cancer; Pancreatic cancer
  • Preclinical Breast cancer

Most Recent Events

  • 23 Sep 2017 University of California plans the ROCKIF phase I/II trial for Ovarian cancer (Second-line therapy) (NCT03287271)
  • 02 Jun 2017 Efficacy and adverse events data from a phase II Window of Opportunity trial in Mesothelioma presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 01 May 2017 Phase-I/II clinical trials in Solid tumours (Late-stage disease, Combination therapy, Second-line therapy or greater) in United Kingdom (PO) (NCT02758587)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top